Anti-obesity medications or ""medications to treat obesity"" instead of ""weight loss drugs"" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Imagem de Miniatura
Arquivos
art_HALPERN_Antiobesity_medications_or_medications_to_treat_obesity_instead_2023.PDF (213.8 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
Autores
HALPERN, Bruno
SANDE-LEE, Simone van de
MIRANDA, Paulo Augusto Carvalho
Citação
ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.67, n.4, article ID e230174, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term ""weight loss drugs"" to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as ""medications to treat obesity"" or ""anti-obesity medications"" conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care.
Palavras-chave
Obesity, weight loss, treatment, drugs, language
URI
https://observatorio.fm.usp.br/handle/OPI/58173
Referências
  1. ABESO, 2016, Diretrizes Brasileiras de Obesidade 2016, V4a
  2. Ahmad NN, 2021, OBES REV, V22, DOI 10.1111/obr.13326
  3. Albury C, 2020, LANCET DIABETES ENDO, V8, P447, DOI 10.1016/S2213-8587(20)30102-9
  4. American Diabetes Association, 2022, Clin Diabetes, V40, P10, DOI 10.2337/cd22-as01
  5. Aronne LJ, 2021, OBESITY, V29, pS9, DOI 10.1002/oby.23086
  6. Associacao Brasileira para o Estudo da Obesidade e Sindrome Metabolica (Abeso)
  7. Sociedade Brasileira de Endocrinologia e Metabologia (SBEM), Obesidade e a Gordofobia-Percepcoes 2022
  8. Bahia L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-440
  9. Bray GA, 2018, ENDOCR REV, V39, P79, DOI 10.1210/er.2017-00253
  10. Cataldi Mauro, 2020, Int J Obes Suppl, V10, P14, DOI 10.1038/s41367-020-0015-3
  11. Caterson ID, 2019, DIABETES OBES METAB, V21, P1914, DOI 10.1111/dom.13752
  12. Chen F, 2019, J MED ECON, V22, P1096, DOI 10.1080/13696998.2019.1652185
  13. Ciciurkaite G, 2019, PUBLIC HEALTH REP, V134, P141, DOI 10.1177/0033354918813102
  14. Colantonio LD, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.010376
  15. Crocker AF, 2019, J MULTIDISCIP HEALTH, V12, P125, DOI 10.2147/JMDH.S140067
  16. de Vries CEE, 2022, OBES REV, V23, DOI 10.1111/obr.13452
  17. Dickinson JK, 2017, DIABETES CARE, V40, P1790, DOI 10.2337/dci17-0041
  18. Drucker DJ, 2018, CELL METAB, V27, P740, DOI 10.1016/j.cmet.2018.03.001
  19. Duncan GE, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-47
  20. Earnshaw VA, 2012, J HEALTH PSYCHOL, V17, P157, DOI 10.1177/1359105311414952
  21. Elangovan A, 2021, OBES SURG, V31, P1105, DOI 10.1007/s11695-020-04987-2
  22. Ezequiel DGA, 2022, Abordagem multidisciplinar do individuo com excesso de peso: a linguagem importa?, V1
  23. Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
  24. Forum Intersetorial para Combate as DCNTs no Brasil, Linguagem Importa! (Language Matters!)-Atualizacao de Linguagem para Diabetes, Obesidade e outras Condicoes Cronicas de Saude
  25. Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017
  26. Geller AI, 2015, NEW ENGL J MED, V373, P1531, DOI 10.1056/NEJMsa1504267
  27. Hall KD, 2018, MED CLIN N AM, V102, P183, DOI 10.1016/j.mcna.2017.08.012
  28. Halpern B, 2021, J ENDOCRINOL INVEST, V44, P877, DOI 10.1007/s40618-020-01389-0
  29. Halpern B, 2022, ARCH ENDOCRIN METAB, V66, P936, DOI 10.20945/2359-3997000000571
  30. Halpern B, 2022, ARCH ENDOCRIN METAB, V66, DOI 10.20945/2359-3997000000465
  31. Halpern B, 2020, OBESITY, V28, P1171, DOI 10.1002/oby.22810
  32. Halpern B, 2015, EXPERT OPIN DRUG SAF, V14, P305, DOI 10.1517/14740338.2015.994502
  33. Halpern B, 2015, EXPERT OPIN DRUG SAF, V14, P185, DOI 10.1517/14740338.2015.995088
  34. Hay P, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-04005-y
  35. Hemo B, 2011, DIABETES RES CLIN PR, V94, P269, DOI 10.1016/j.diabres.2011.08.021
  36. Phan K, 2014, CURR PHARM DESIGN, V20, P6314, DOI 10.2174/1381612820666140620162629
  37. Kyle TK, 2014, OBESITY, V22, P1211, DOI 10.1002/oby.20727
  38. Latner JD, 2014, EAT BEHAV, V15, P586, DOI 10.1016/j.eatbeh.2014.08.014
  39. LeBlanc ES, 2011, ANN INTERN MED, V155, P434, DOI 10.7326/0003-4819-155-7-201110040-00006
  40. Mannucci E, 2008, NUTR METAB CARDIOVAS, V18, P342, DOI 10.1016/j.numecd.2007.03.010
  41. Marso SP, 2016, NEW ENGL J MED, V375, P1834, DOI 10.1056/NEJMoa1607141
  42. Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
  43. Mechanick JI, 2017, ENDOCR PRACT, V23, P372, DOI 10.4158/EP161688.PS
  44. Nadolsky K, 2023, ENDOCR PRACT, V29, P417, DOI 10.1016/j.eprac.2023.03.272
  45. Nauck MA, 2021, DIABETES OBES METAB, V23, P5, DOI 10.1111/dom.14496
  46. Oshman L, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0284474
  47. Pearl RL, 2020, ANN BEHAV MED, V54, P904, DOI 10.1093/abm/kaaa026
  48. Pomeranz JL, 2013, AM J PUBLIC HEALTH, V103, P220, DOI [10.2105/AJPH.2012.300962, 10.2105/AJPH.2012.301150]
  49. Puhl RM, 2020, AM PSYCHOL, V75, P274, DOI 10.1037/amp0000538
  50. Raynor HA, 2016, J ACAD NUTR DIET, V116, P129, DOI 10.1016/j.jand.2015.10.031
  51. Rubino F, 2023, LANCET DIABETES ENDO, V11, P226, DOI 10.1016/S2213-8587(23)00058-X
  52. Rubino F, 2020, NAT MED, DOI 10.1038/s41591-020-0803-x
  53. Ryan DH, 2020, AM HEART J, V229, P61, DOI 10.1016/j.ahj.2020.07.008
  54. Sasdelli AS, 2018, EAT WEIGHT DISORD-ST, V23, P205, DOI 10.1007/s40519-017-0475-9
  55. Schwartz MW, 2017, ENDOCR REV, V38, P267, DOI 10.1210/er.2017-00111
  56. Sharma AM, 2023, EUROPEAN C OBESITY
  57. Sharma AM, 2017, OBESITY, V25, P660, DOI 10.1002/oby.21801
  58. Siebenhofer A, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007654.pub5
  59. Speight J, 2012, DIABETES RES CLIN PR, V97, P425, DOI 10.1016/j.diabres.2012.03.015
  60. Swinburn BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8
  61. Tanaka N, 2022, J DIABETES INVEST, DOI 10.1111/jdi.13894
  62. Thomas CE, 2016, OBESITY, V24, P1955, DOI 10.1002/oby.21533
  63. Thomas DD, 2019, OBESITY, V27, P1168, DOI 10.1002/oby.22503
  64. Tronieri JS, 2018, OBESITY, V26, P299, DOI 10.1002/oby.22081
  65. Van Alsten SC, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200244
  66. Wadden TA, 2021, JAMA-J AM MED ASSOC, V325, P1403, DOI 10.1001/jama.2021.1831
  67. Wadden TA, 2020, OBESITY, V28, P529, DOI 10.1002/oby.22726
  68. Wadden TA, 2011, NEW ENGL J MED, V365, P1969, DOI 10.1056/NEJMoa1109220
  69. Wadden TA, 2011, OBESITY, V19, P110, DOI 10.1038/oby.2010.147
  70. Weghuber D, 2023, PEDIATR OBES, V18, DOI 10.1111/ijpo.13024
  71. Wharton S, 2020, CAN MED ASSOC J, V192, pE875, DOI 10.1503/cmaj.191707
  72. Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4
  73. Wilding JPH, 2022, DIABETES OBES METAB, V24, P1553, DOI 10.1111/dom.14725
  74. Wilson ER, 2017, OBESITY, V25, P370, DOI 10.1002/oby.21746
  75. World Health Organization (WHO), 2016, 10 Facts on obesity
  76. Xia Y, 2015, OBESITY, V23, P1721, DOI 10.1002/oby.21136
  77. Zubiaurre PR, 2017, OBES SURG, V27, P3273, DOI 10.1007/s11695-017-2776-5

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/03